Swiftmerge Acquisition ROE 1970-1969 | ANNA

Current and historical return on equity (ROE) values for Swiftmerge Acquisition (ANNA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Swiftmerge Acquisition ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.042B $0.000B
Swiftmerge Acquisition Corp. entered into definitive merger agreement with HDL Therapeutics Inc.
Stock Name Country Market Cap PE Ratio
NPK (NPKI) United States $0.626B 27.85
Performant Healthcare (PHLT) United States $0.245B 0.00
FTAC Emerald Acquisition (FLDD) United States $0.158B 0.00
Insight Acquisition (AMOD) United States $0.023B 0.00
Hanryu Holdings (GITS) South Korea $0.017B 0.00
Pieris Pharmaceuticals (PVLA) United States $0.016B 0.00
LQR House (YHC) United States $0.011B 0.00
ATIF Holdings (ZBAI) China $0.009B 0.00
Lion Electric (LEVGQ) Canada $0.000B 0.00